Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way | Zendy

Otávio Augusto Chaves | Zendy; Carolina Q. Sacramento | Zendy; Natália Fintelman-Rodrigues | Zendy; Jairo R. Temerozo | Zendy; Filipe S. PereiraDutra | Zendy; Daniella M. Mizurini | Zendy; Robson Q. Monteiro | Zendy; Leonardo Vázquez | Zendy; Patrı́cia T. Bozza | Zendy; Hugo C. CastroFariaNeto | Zendy; Thiago Moreno L. Souza | Zendy

Open Access

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

Author(s) -

Otávio Augusto Chaves,

Carolina Q. Sacramento,

Natália Fintelman-Rodrigues,

Jairo R. Temerozo,

Filipe S. PereiraDutra,

Daniella M. Mizurini,

Robson Q. Monteiro,

Leonardo Vázquez,

Patrı́cia T. Bozza,

Hugo C. CastroFariaNeto,

Thiago Moreno L. Souza

Publication year - 2022

Publication title -

journal of molecular cell biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.825

H-Index - 62

eISSN - 1674-2788

pISSN - 1759-4685

DOI - 10.1093/jmcb/mjac039

Subject(s) - apixaban , replication (statistics) , virology , covid-19 , protease , viral replication , protease inhibitor (pharmacology) , biology , computational biology , medicine , enzyme , viral load , virus , rivaroxaban , biochemistry , atrial fibrillation , disease , outbreak , warfarin , infectious disease (medical specialty) , pathology , antiretroviral therapy , cardiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research